Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion

European Journal of Clinical Pharmacology

Volumn 55, Issue 1, 1999, Pages 61-67

  Ericsson, H ^a   Fakt, C ^a   Hoglund L ^a   Jolin Mellgard A ^a   Nordlander, M ^a   Sunzel, M ^a   Regardh C G ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Calcium antagonist; Clevidipine; Perioperative hypertension

Indexed keywords

4 (2,3 DICHLOROPHENYL) 1,4 DIHYDRO 2,6 DIMETHYL 3,5 PYRIDINEDICARBOXYLIC ACID METHYL ESTER; CALCIUM ANTAGONIST; CLEVIDIPINE; DRUG METABOLITE; TRITIUM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; PRIORITY JOURNAL; VENOUS BLOOD;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PYRIDINES; TIME FACTORS;

EID: 0033003861     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050594     Document Type: Article

References (33)

1. Vuylsteke A, Feneck R, Latimer R, Levy J, Lynch C, Ricksten SE, Jolin-Mellgård Å (1996) Type of perioperative treatment delays extubation and prolongs ICU stay in cardiac surgery. Br J Anaesth 76: A30
2. Viljoen JF, Estafanous GF, Tarazi RC (1976) Acute hypertension immediately after coronary artery surgery. J Thorac Cardiovasc Surg 71: 548-550
3. Gray RJ (1988) Postcardiac surgical hypertension. J Cardiothorac Anesth 2: 291-298
4. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR, James TN (1980) Pathogenesis of paroxymal hypertension developing during and after coronary bypass surgery: a study of haemodynamic and humoral factors. Am J Cardiol 46: 559-565
5. Hoar PF, Stone JG, Faltas AN, Bendixen HH, Head RJ, Berkowitz BA (1980) Haemodynamic and adrenergic responses to anesthesia and operation for myocardial revascularization. J Thorac Cardiovasc Surg 80: 242-248
6. James TN, Hageman GR, Urthaler F (1979) Anatomic and physiologic considerations of a cardigenic hypertensive reflex. Am J Cardiol 4: 852-859
7. Pratilas V, Pratila MG, Vlachakis ND, Owitz S, Dimich I (1980) Sympathic nervous system tonicity and post coronary artery bypass hypertension. Acta Anaesthesiol Scand 24: 69-73
8. Levy JH (1993) The ideal agent for perioperative hypertension and potential cytoprotective effects. Acta Anaesthesiol Scand Suppl 37: 20-25
9. van Zwieten PA, van Wezel HB (1993) Antihypertensive drug treatment in the perioperative period. J Cardiothorac Vasc Anesth 7: 213-226
10. Levy JH, Huraux C, Nordlander M (1997) Treatment of perioperative hypertension. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanely and Belfus, Philadelphia, pp 345-358
11. Holm G, Hanssen K, Svensson L (1985) Use of dodecyl sulfate as an esterase inhibitor before gas-chromatographic determination of labile β-adrenoceptor blocking drugs. Clin Chem 31: 868-870
12. Fakt C, Stenhoff H (1998) Determination of an ultrashort-acting antihypertensive dihydropyridine in blood using capillary gas chromatography mass spectrometry and the primary metabolite using liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl (in press)
13. Yamaoka K, Nakagawa T, Uno T (1976) Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6: 165-175
14. Ericsson H, Tholander B, Regårdh CG (1999) In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolized by esterases, in different animal species and man. European J Pharm Sci (in press)
15. Rowland M, Riegelman S (1968) Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. J Pharm Sci 57: 1313-1319
16. Höglund L, Ericsson H (1997) Astra Hässle Clinical Report SH-SAD-0002, Pharmacokinetics of H 324/38 in healthy male subjects after intravenous infusion
17. Ericsson H, Fakt C, Jolin-Mellgård Å, Nordlander M, Sohtell L, Sunzel M, Regårdh CG (1999) Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol (in press)
18. Chiou WL (1989) The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin Pharmacokinet 17: 175-199 (part I) and Clin Pharmacokinet 17: 275-290 (part II)
19. Gumbleton M, Öie S, Verotta D (1994) Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences. Br J Clin Pharmacol 38: 389-400
20. Stanski DR, Hudson RJ, Homer TD, Saidman LJ, Meathe E (1984) Pharmacodynamic modeling of thiopental anesthesia. J Pharmacokinet Biopharm 12: 223-240
21. Fisher DM (1996) (Almost) everything you learned about pharmacokinetics was (somewhat) wrong. Anesth Analg 83: 901-903
22. Tuk B, Herben MM, Mandema JW, Danhof M (1998) Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. J Pharmacol Exp Ther 284: 202-207
23. Vuylsteke A, Milner QJ, Ericsson H, Mur D, Dunning J, Latimer RD (1998) Clevidipine and pulmonary extraction during coronary artery bypass graft surgery. Br J Anaesth 80: A10
24. Chism JP, Rickert DE (1996) The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusion. Drug Metab Dispos 24: 34-40
25. Dershwitz M, Hoke JF, Rosow CE, Michalowski P, Connors PM, Muir KT, Dienstag JL (1996) Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 84: 812-820
26. Regårdh CG, Bäärnhielm C, Edgar B, Hoffman K-J (1990) Pharmacokinetics and biotransformation of 1,4-dihydropyridine calcium antagonists. In: Gibson GG (ed) Progress in drug metabolism 12. Taylor and Francis, pp 41-86
27. Ohtake Y, Sakamoto T, Nishioka R, Uno K, Tabata S (1992) Metabolic fate of felodipine in man. In search of new dihydropyridine metabolites. Drug Invest 4: 528-534
28. Folkow B, Neil E (1971) In circulation. Oxford University Press, New York
29. van Heereveld H, Wollersheim H, Gough K, Thien T (1988) Intravenous nicardipine in Raynaud's phenomenon: a controlled trial. J Cardiovasc Pharmacol 11: 68-74
30. Kleinbloesem CH, Van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD (1987) Rate of increase in plasma concentration of nifedipine as a major determinant of its haemodynamic effects in humans. Clin Pharmacol Ther 41: 26-40
31. Cohen AF, van Hall M, van Harten J, Schoemaker RC, Johansson P, Breimer DD Visser R, Edgar B (1990) The influence of infusion rate on the hemodynamic effects of felodipine. Clin Pharmacol Ther 48: 309-317
32. Tanaka M, Nishikawa T (1997) Arterial baroreflex function in humans anesthetized with sevoflurane. Anesthesiology 87: A132
33. Kieler-Jensen N, Jolin-Mellgård Å, Nordlander M, Ricksten SE (1998) Myocardial circulatory and metabolic effects of clevidipine after coronary artery bypass grafting (CABG) Br J Anaesth 78: A12